<DOC>
	<DOC>NCT01588496</DOC>
	<brief_summary>A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).</brief_summary>
	<brief_title>Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities</brief_title>
	<detailed_description>Study Masking: Part A: Open Label Part B: Double Blind</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Males and females ≥ 12 to ≤ 80 years of age Diagnosis of homozygous familial hypercholesterolemia Stable lipidlowering therapies for at least 4 weeks LDL cholesterol ≥ 130 mg/dl (3.4 mmol/L) Triglyceride ≤ 400 mg/dL (4.5 mmol/L) Bodyweight of ≥ 40 kg at screening. LDL or plasma apheresis within 8 weeks prior to randomization New York Heart Association (NYHA) class III or IV or last known left ventricular ejection fraction &lt; 30% Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of randomization Planned cardiac surgery or revascularization Uncontrolled cardiac arrhythmia Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>familial hypercholesterolemia</keyword>
	<keyword>homozygous familial hypercholesterolemia</keyword>
</DOC>